Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Below is a roundup of payer-centric news headlines you may have missed during the month of January 2025. | You may have ...

Taco Bell is re-upping its value menu game with the introduction of $5, $7 and $9 luxe cravings boxes, while TikTok is ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...